Filing identity and reporting period
Important identity discrepancy: The request identifies Gyre Therapeutics, Inc., but the supplied Form 10-Q is for Catalyst Biosciences, Inc. It covers the quarter ended June 30, 2018, was signed August 2, 2018, and reports unaudited results. This summary describes the supplied filing, not a Gyre filing.
Catalyst was a clinical-stage biotechnology company developing therapies primarily for hemophilia. It had no approved products or commercial product sales.
Financial performance and position
Amounts below are in millions of dollars except per-share data.
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Contract revenue | $0.0 | $0.111 | $0.006 | $0.382 |
| Research and development expense | $3.889 | $3.401 | $7.660 | $5.481 |
| General and administrative expense | $3.225 | $2.654 | $6.139 | $5.017 |
| Net loss | $6.482 | $5.877 | $11.524 | $10.015 |
| Net loss per share | $0.54 | $2.53 | $1.10 | $5.82 |
Q2 operating expenses rose 17% year over year; six-month expenses rose 31%. The company reported no gross margin because it had no product sales. Revenue was largely from the ISU Abxis collaboration, whose performance obligations concluded in February 2018. Q2 operating loss was $7.114 million; six-month operating loss was $13.793 million. Net loss was partly offset by interest and other income of $0.632 million in Q2 and $2.269 million for the half year; the six-month amount included $1.5 million in milestones related to previously sold neuronal nicotinic receptor assets.
At June 30, 2018, cash and cash equivalents were $46.533 million, short-term investments $89.613 million, and restricted cash $0.175 million. The filing cites $136.1 million of cash, cash equivalents and short-term investments. Total assets were $139.542 million, current liabilities $2.439 million, and total liabilities $2.579 million. The redeemable convertible notes were repaid at maturity in February 2018; none remained outstanding at quarter-end.
For the six months, operating cash use was $12.520 million, investing cash use $71.838 million, and financing cash inflow $111.261 million. Financing included $106.762 million net proceeds from a February common-stock offering and $9.545 million from warrant exercises, partly offset by $5.082 million to repay notes. The company reported an accumulated deficit of $184.811 million. Common shares outstanding increased from 6,081,230 at December 31, 2017 to 11,942,729 at June 30, 2018.
Material changes versus the prior comparable period
- Contract revenue fell to zero in Q2 and was nearly eliminated for the first half as ISU Abxis revenue recognition ended; adoption of ASC 606 also shifted recognition timing and produced a $0.207 million opening accumulated-deficit adjustment.
- First-half R&D expense increased 40%, reflecting higher personnel and manufacturing costs; G&A rose 22%, mainly due to personnel costs.
- Six-month net loss increased 15%, despite substantially higher other income. Operating cash use increased from $8.694 million to $12.520 million.
- The February offering and warrant exercises materially increased cash and share count. The company also repaid the remaining convertible notes, eliminating that debt.
Outlook, commentary, and risks
- Management said existing cash, cash equivalents and short-term investments were expected to fund requirements for at least 12 months from the filing date. The estimate depends on assumptions; additional capital may be needed, and financing may be unavailable or dilutive. Management expected increasing operating losses and R&D spending, particularly for MarzAA and CB 2679d/ISU 304.
- MarzAA was in a Phase 2/3 subcutaneous trial. As of July 31, 2018, five participants had enrolled; interim data was expected in the second half of 2018. The filing described early observations but cautioned that the small trial was ongoing.
- CB 2679d/ISU 304 had encouraging activity data in earlier cohorts, but two participants in Cohort 6 developed neutralizing antibodies. The antibodies bound the engineered candidate and furin, a manufacturing constituent, but not wild-type Factor IX. Catalyst was investigating the cause and impact before dosing further Cohort 6 participants or starting Phase 2b; timing and study design could change.
- Other risks include clinical-trial failure or delay, patient enrollment, manufacturing and third-party reliance, regulatory approval, competition, and the need for additional financing. Pfizer may receive up to $17.5 million in contingent milestone payments and a single-digit royalty on covered product sales; these contingent amounts were not included in contractual-obligation totals.
- The filing reported no material legal proceedings or off-balance-sheet arrangements. Management concluded disclosure controls were effective as of June 30, 2018.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Catalyst Biosciences, Inc., not Gyre Therapeutics, Inc.
- Verify the clinical status and subsequent results of MarzAA, including trial enrollment, efficacy, and antibody monitoring.
- Track the investigation into CB 2679d/ISU 304 neutralizing antibodies and any resulting manufacturing, safety, or Phase 2b changes.
- Assess cash runway against clinical and manufacturing commitments, ongoing operating cash burn, and potential future financing or dilution.
- Confirm the treatment of ASC 606 collaboration revenue and distinguish recurring investment income from the one-time $1.5 million milestone receipt.